Importantly, PD-L1 can be upregulated in tumor cells via inflammatory signals, mainly under the influence of IFN-γ produced by immune cells and activation of downstream pathways such as EGFR, MAPK, or PI3K-Akt (29–34). The gene discussed is IFNG; the disease is neoplasm.